Back to Journals » Lung Cancer: Targets and Therapy » Volume 2

Effectiveness of maintenance treatments for nonsmall cell lung cancer

Authors Eadens, Robinson, Price K

Published 22 July 2011 Volume 2011:2 Pages 29—39

DOI https://doi.org/10.2147/LCTT.S12507

Review by Single anonymous peer review

Peer reviewer comments 3



Matthew J Eadens, Steven I Robinson, Katharine AR Price
Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA

Abstract: Maintenance therapy for advanced nonsmall cell lung cancer has shown some clinical benefit for patients by improving progression-free survival and, to a lesser extent, overall survival. Two main strategies exist for maintenance therapy, ie, continuation and switch maintenance. Continuation maintenance involves the continued use of one of the induction drugs beyond 4–6 cycles of initial treatment. Switch maintenance utilizes a third agent initiated after first-line chemotherapy. Both cytotoxic agents and targeted agents have been studied. Switch maintenance therapy with pemetrexed in nonsquamous tumors and erlotinib appear to show the most clear clinical benefit. Continuation maintenance with bevacizumab has shown improvement in progression-free survival. Data concerning the role of cetuximab for maintenance is conflicting. Toxicity, quality of life, and cost are important confounding issues that need to be considered. Several ongoing Phase III trials are investigating strategies to improve on the current agents as well as testing promising new therapies.

Keywords: lung cancer, chemotherapy, maintenance therapy, targeted therapy

Creative Commons License © 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.